Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Maya F. Kotturi"'
Autor:
Kevin C. Hart, Daniel Santos, Deepal Pandya, Rong Deng, Keyu LI, Yinghui Guan, Genevive Hernandez, Thomas Manley, Maya K. Leabman, Paul R. Hinton, Liqin Liu, Angus M. Sinclair, Albert F. Candia, Stephen F. Carroll, Bruce A. Keyt, Maya F. Kotturi
Publikováno v:
HemaSphere, Vol 7, p e630565c (2023)
Externí odkaz:
https://doaj.org/article/eec65130efac469185c57723fcdf2227
Autor:
Jessica Li, Sarah Whelan, Maya F. Kotturi, Deborah Meyran, Criselle D’Souza, Kyle Hansen, Spencer Liang, John Hunter, Joseph A. Trapani, Paul J. Neeson
Publikováno v:
Haematologica, Vol 106, Iss 12 (2020)
This study explored the novel immune checkpoint poliovirus receptor- related immunoglobulin domain-containing (PVRIG) in acute myeloid leukemia (AML). We showed that AML patient blasts consistently expressed the PVRIG ligand (poliovirus receptor-rela
Externí odkaz:
https://doaj.org/article/2b005a11c33b42b39ed8bb883feb51b5
Autor:
Spencer C. Liang, Drew M. Pardoll, Mark White, Ie-Ming Shih, Tian-Li Wang, Amanda Nickles Fader, Janis M. Taube, Abha Soni, Benjamin Murter, David Bernados, Kyle Hansen, Liat Dassa, Sandeep Kumar, Ilan Vaknin, Ling Leung, Sudipto Ganguly, Ofer Levy, Maya F. Kotturi, Eran Ophir, Sarah Whelan
Although checkpoint inhibitors that block CTLA-4 and PD-1 have improved cancer immunotherapies, targeting additional checkpoint receptors may be required to broaden patient response to immunotherapy. PVRIG is a coinhibitory receptor of the DNAM/TIGIT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60c18601ea04a671a92c7d8dc05a7e4c
https://doi.org/10.1158/2326-6066.c.6549019.v1
https://doi.org/10.1158/2326-6066.c.6549019.v1
Autor:
Spencer C. Liang, Drew M. Pardoll, Mark White, Ie-Ming Shih, Tian-Li Wang, Amanda Nickles Fader, Janis M. Taube, Abha Soni, Benjamin Murter, David Bernados, Kyle Hansen, Liat Dassa, Sandeep Kumar, Ilan Vaknin, Ling Leung, Sudipto Ganguly, Ofer Levy, Maya F. Kotturi, Eran Ophir, Sarah Whelan
Figure captions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::400dcce86901a5d06427dbf10db453fb
https://doi.org/10.1158/2326-6066.22539211
https://doi.org/10.1158/2326-6066.22539211
Autor:
Spencer C. Liang, Drew M. Pardoll, Mark White, Ie-Ming Shih, Tian-Li Wang, Amanda Nickles Fader, Janis M. Taube, Abha Soni, Benjamin Murter, David Bernados, Kyle Hansen, Liat Dassa, Sandeep Kumar, Ilan Vaknin, Ling Leung, Sudipto Ganguly, Ofer Levy, Maya F. Kotturi, Eran Ophir, Sarah Whelan
Supplementary Figures and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eff2e655637bca62cbd6090b19e3bb4
https://doi.org/10.1158/2326-6066.22539208
https://doi.org/10.1158/2326-6066.22539208
Autor:
Genevive H. Hernandez, John So, Kathryn A. Logronio, Maya F. Kotturi, Won Seog Kim, Philippe Armand, Chan Y. Cheah, Ajay K. Gopal, Ian W. Flinn, Gareth P. Gregory, Matthew J. Matasar, Loretta J. Nastoupil, Catherine S. Diefenbach, Sung-Soo Yoon, Matthew Ku, Ibrahim Qazi, Maya K. Leabman, Iris Sison, Bruce A. Keyt, Chris H. Takimoto, Thomas J. Manley, Elizabeth L. Budde
Publikováno v:
Blood. 140:6436-6438
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69c364a4faace6cccfd490fae66a692a
https://doi.org/10.1182/blood-2022-163235
https://doi.org/10.1182/blood-2022-163235
Autor:
Gady Cojocaru, Margaret L. Tang, Patrick Wall, Sandeep Kumar, Eran Ophir, Hsin-Yuan Cheng, John J. Hunter, Ling Leung, Andrew W. Drake, Maya F. Kotturi, Masha Frenkel, Kathryn Logronio, David Bernados, Moran Galperin, Kyle Hansen, Spencer Liang, Samir Qurashi, Mark A. White, Zoya Alteber, Sarah Whelan
Publikováno v:
Cancer Immunology, Immunotherapy. 70:3525-3540
Immune checkpoint inhibitors (ICIs) have emerged as promising therapies for the treatment of cancer. However, existing ICIs, namely PD-(L)1 and CTLA-4 inhibitors, generate durable responses only in a subset of patients. TIGIT is a co-inhibitory recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3956f7736390726882c24308715f5566
https://doi.org/10.1007/s00262-021-02921-8
https://doi.org/10.1007/s00262-021-02921-8
Autor:
Keyu Li, Rui Yun, Min Chai, Poonam Yakkundi, Rodnie Rosete, Gene Li, Liqin Liu, Mandy Li, Daniel Santos, Kevin C. Hart, Dean Ng, Paul R. Hinton, Umesh Muchhal, Thomas Manley, Maya F. Kotturi, Stephen F. Carroll, Angus M. Sinclair, Bruce A. Keyt
Publikováno v:
Cancer Research. 83:2959-2959
Multiple myeloma (MM), a cancer of plasma cells, occurs in ~34,000 new patients every year in the USA. Although therapeutic regimens, including anti-CD38 monospecific IgG antibodies such as daratumumab and isatuximab in combination with chemotherapie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9160ef0b429602f3396a7495085005d0
https://doi.org/10.1158/1538-7445.am2023-2959
https://doi.org/10.1158/1538-7445.am2023-2959
Autor:
Thierry D. Giffon, Melanie Desbois, Poonam Yakkundi, Susan Calhoun, Keerthana Sekar, Carolyn Denson, Tasnim Kothambawala, Alexander Pearson, Sivani Pandey, Deepal Pandya, Rodnie Rosete, Daniel Machado, Pat Raichlen, Dean Ng, Abhinav R. Jain, Roel Funke, Eric Humke, Paul R. Hinton, Beatrice Wang, Bruce A. Keyt, Maya F. Kotturi, Angus M. Sinclair
Publikováno v:
Cancer Research. 83:5660-5660
Immunostimulatory cytokines are a promising immunotherapy for the treatment of advanced malignancies, but generally have been associated with severe toxicities when administered systemically. The recent development of antibody-cytokine fusion protein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ba347862003d19d9ed4bb9499b53020
https://doi.org/10.1158/1538-7445.am2023-5660
https://doi.org/10.1158/1538-7445.am2023-5660
Autor:
Gene Li, Ling Wang, Poonam Yakkundi, Paul Hinton, Deepal Pandya, Keerthana Sekar, Rodine Rosete, Zhongde Ye, Nardeen Hanna, Maya F. Kotturi, Liz Bogaert, Jiyoung Hong, Christina Tsai, Thomas Manley, Bruce A. Keyt, Angus M. Sinclair, Liqin Liu
Publikováno v:
Cancer Research. 83:2933-2933
Novel therapeutics are needed for the effective treatment of acute myeloid leukemia (AML), as standard chemotherapeutics are poorly tolerated and ~50% of patients relapse primarily due to the incomplete elimination of leukemia stem cells (LSCs). CD12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6bab38bf508e62130e1680f5acf6766
https://doi.org/10.1158/1538-7445.am2023-2933
https://doi.org/10.1158/1538-7445.am2023-2933